Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Kiniksa Pharmaceuticals International, plc (KNSA) had Stock-Based Compensation of $10.06M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$214.27M |
|
$22.59M |
|
$20.80M |
|
$193.47M |
|
$185.00M |
|
$29.27M |
|
$3.41M |
|
$32.68M |
|
$32.68M |
|
$22.59M |
|
$22.59M |
|
$22.59M |
|
$22.59M |
|
$29.27M |
|
$29.73M |
|
76.52M |
|
82.41M |
|
$0.30 |
|
$0.27 |
|
| Balance Sheet Financials | |
$594.17M |
|
$1.99M |
|
$231.11M |
|
$825.28M |
|
$156.61M |
|
-- |
|
$62.98M |
|
$219.59M |
|
$605.69M |
|
$590.69M |
|
$605.69M |
|
76.69M |
|
| Cash Flow Statement Financials | |
$50.20M |
|
$-31.92M |
|
$6.07M |
|
$165.60M |
|
$189.95M |
|
$24.36M |
|
|
Stock-Based Compensation |
$10.06M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
90.29% |
|
13.66% |
|
13.66% |
|
-- |
|
15.25% |
|
10.54% |
|
$50.04M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
0.28 |
|
9.23 |
|
9.76 |
|
3.73% |
|
3.82% |
|
2.74% |
|
3.73% |
|
$7.90 |
|
$0.61 |
|
$0.61 |
|